ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.519,41
-0,43%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08998
0,00%
Bitcoin
63.262,48
-2,45%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sana Biotechnology Inc (SANA)

  7. Sana Biotechnology Inc (SANA) News

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SANA
DatumZeitQuelleÜberschriftSymbolFirma
09/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
09/06/202322h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
09/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
09/06/202301h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
07/06/202312h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
31/05/202322h05GlobeNewswire Inc.Sana Biotechnology to Present at June 2023 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
24/05/202322h55Edgar (US Regulatory)Amended Report of Proposed Sale of Securities (144/a)NASDAQ:SANASana Biotechnology Inc
16/05/202312h00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:SANASana Biotechnology Inc
08/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SANASana Biotechnology Inc
08/05/202322h35GlobeNewswire Inc.Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully FunctionalNASDAQ:SANASana Biotechnology Inc
08/05/202322h27Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
08/05/202322h05GlobeNewswire Inc.Sana Biotechnology Reports First Quarter 2023 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
03/05/202322h05GlobeNewswire Inc.Sana Biotechnology to Present at May 2023 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
02/05/202322h30GlobeNewswire Inc.Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingNASDAQ:SANASana Biotechnology Inc
01/05/202322h06Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:SANASana Biotechnology Inc
28/04/202322h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
26/04/202314h13Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SANASana Biotechnology Inc
24/04/202322h05GlobeNewswire Inc.Sana Biotechnology to Host Research & Development DayNASDAQ:SANASana Biotechnology Inc
19/04/202322h05GlobeNewswire Inc.Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual MeetingNASDAQ:SANASana Biotechnology Inc
13/04/202315h00GlobeNewswire Inc.Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor ResponsesNASDAQ:SANASana Biotechnology Inc
12/04/202322h05GlobeNewswire Inc.Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical ModelNASDAQ:SANASana Biotechnology Inc
11/04/202322h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
11/04/202322h26Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SANASana Biotechnology Inc
10/04/202322h05GlobeNewswire Inc.Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D OrganizationNASDAQ:SANASana Biotechnology Inc
06/04/202322h47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
06/04/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
16/03/202322h17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:SANASana Biotechnology Inc
16/03/202321h28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SANASana Biotechnology Inc
16/03/202321h05GlobeNewswire Inc.Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
15/03/202321h20Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA

Kürzlich von Ihnen besucht

BIT
F17506
Vontobel Financial Produ...
NYSE
SRC
Spirit Realty Capital
BIT
F09895
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten